Monika Joshi, MD, MRCP - Penn State Cancer Institute
Researcher Profile
Monika Joshi, MD, MRCP
Associate Professor, Department of Medicine
Endowed Associate Professor in Cancer Clinical Investigation, Department of Medicine
Division of Hematology and Oncology
Assistant Professor, Department of Medicine
Endowed Associate Professor in Cancer Clinical Investigation, Department of Medicine
Division of Hematology and Oncology
Assistant Professor, Department of Medicine
Scientific Program:Next-Generation Therapies
Disease Teams:
Cancer Institute, Genitourinary Cancer Team
Research Interests
Dr. Monika Joshi’s research focus is in the field of genitourinary tumors, particularly in the field of immunotherapy and targeted therapy.
- Therapeutics
- Neoplasms
- Carcinoma
- Urinary Bladder Neoplasms
- Survival
- Drug Therapy
- Prostatic Neoplasms
- Non-Small Cell Lung Carcinoma
- Immunotherapy
- Progression-Free Survival
- Renal Cell Carcinoma
- Radiotherapy
Clinical Trials
NRG-GU011: A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)
A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Evaluation of Biomarkers in Bladder Cancer Patients in the Neoadjuvant Setting
Phase III Study of PET-Directed Local or Systemic Therapy Intensification in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence
Phase III Randomized Trial Of Concurrent Chemoradiotherapy With or Without Atezoluzumab in Localized Muscle Invasive Bladder Cancer
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Phase 2 Study of Bladder-SparIng ChemoradiatioN with CIPosItive bladdeR cancEr (INSPIRE)EA8185
A phase 1b, Open-label Study to Evaluate the Safety, Tolerability Pharmacokinetics Immunogenicity, and Antitumor Activity of MEDI5752 in Combination with Axitinib in Subjects with Advanced Cell Carcinoma
Angelica Herbal Supplement AGN-CognI.Q Acute Dose Safety and Pharmacokinetics (PK) Dose-Response in Prostate Cancer Patients (PK Dose Trial)
APG-115 - A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)
Tissue and Blood Collection from Patients with Suspected Lung Cancer
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Renal Cell Cancer (PDIGREE)
Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy
PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
One Time Tissue and Blood Collection from Patients with Lung Cancer at Risk for Developing Lung Cancer
The COVID-19 and Cancer Consortium (CCC19) Registry
MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer
Recent Publications
2023
Joshi, M, Tuanquin, L, Zhu, J, Walter, V, Schell, T, Kaag, M, Kilari, D, Liao, J, Holder, SL, Emamekhoo, H, Sankin, A, Merrill, S, Zheng, H, Warrick, J, Hauke, R, Gartrel, B, Stein, M, Drabick, J, Degraff, DJ & Zakharia, Y 2023, 'Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: Results from phase II study, BTCRC-GU15-023', Journal for ImmunoTherapy of Cancer, vol. 11, no. 2, e006551. https://doi.org/10.1136/jitc-2022-006551
Venkatesulu, BP, Liauw, SL, Joshi, M, Baumann, BC, Yoo, R, Roupret, M, Choudhury, A, Efstathiou, JA, Murthy, V, Sargos, P & Solanki, AA 2023, 'Multidisciplinary Management and Radiotherapy Recommendations for Clinically and Pathologically Node-positive Bladder Cancer', Seminars in Radiation Oncology, vol. 33, no. 1, pp. 35-50. https://doi.org/10.1016/j.semradonc.2022.10.005
2022
Weng, X, Shen, C, Van Scoy, LJ, Boltz, M, Joshi, M & Wang, L 2022, 'A comparison of end-of-life care patterns between older patients with both cancer and Alzheimer's disease and related dementias versus those with only cancer', Journal of Geriatric Oncology, vol. 13, no. 8, pp. 1111-1121. https://doi.org/10.1016/j.jgo.2022.08.011
Weng, X, Shen, C, Vasekar, M, Boltz, M, Joshi, M, Van Scoy, LJ & Wang, L 2022, 'Alzheimer's disease and related dementias is a risk factor for lower utilization of breast cancer screening and unstaged cancer diagnosis: Observational study from SEER-Medicare 2004–2016 data', Journal of Geriatric Oncology. https://doi.org/10.1016/j.jgo.2022.11.006
Lü, J, Jiang, C, Schell, TD, Joshi, M, Raman, JD & Xing, C 2022, 'Angelica gigas: Signature Compounds, In Vivo Anticancer, Analgesic, Neuroprotective and Other Activities, and the Clinical Translation Challenges', American Journal of Chinese Medicine, vol. 50, no. 6, pp. 1475-1527. https://doi.org/10.1142/S0192415X2250063X
Makrakis, D, Talukder, R, Lin, GI, Diamantopoulos, LN, Dawsey, S, Gupta, S, Carril-Ajuria, L, Castellano, D, de Kouchkovsky, I, Koshkin, VS, Park, JJ, Alva, A, Bilen, MA, Stewart, TF, McKay, RR, Tripathi, N, Agarwal, N, Vather-Wu, N, Zakharia, Y, Morales-Barrera, R, Devitt, ME, Cortellini, A, Fulgenzi, CAM, Pinato, DJ, Nelson, A, Hoimes, CJ, Gupta, K, Gartrell, BA, Sankin, A, Tripathi, A, Zakopoulou, R, Bamias, A, Murgic, J, Fröbe, A, Rodriguez-Vida, A, Drakaki, A, Liu, S, Lu, E, Kumar, V, Lorenzo, GD, Joshi, M, Isaacsson-Velho, P, Buznego, LA, Duran, I, Moses, M, Jang, A, Barata, P, Sonpavde, G, Yu, EY, Montgomery, RB, Grivas, P & Khaki, AR 2022, 'Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma', Clinical Genitourinary Cancer, vol. 20, no. 5, pp. e440-e452. https://doi.org/10.1016/j.clgc.2022.06.001
Talukder, R, Makrakis, D, Lin, GI, Diamantopoulos, LN, Dawsey, S, Gupta, S, Carril-Ajuria, L, Castellano, D, de Kouchkovsky, I, Jindal, T, Koshkin, VS, Park, JJ, Alva, A, Bilen, MA, Stewart, TF, McKay, RR, Tripathi, N, Agarwal, N, Vather-Wu, N, Zakharia, Y, Morales-Barrera, R, Devitt, ME, Cortellini, A, Fulgenzi, CAM, Pinato, DJ, Nelson, A, Hoimes, CJ, Gupta, K, Gartrell, BA, Sankin, A, Tripathi, A, Zakopoulou, R, Bamias, A, Murgic, J, Fröbe, A, Rodriguez-Vida, A, Drakaki, A, Liu, S, Lu, E, Kumar, V, Lorenzo, GD, Joshi, M, Isaacsson-Velho, P, Buznego, LA, Duran, I, Moses, M, Barata, P, Sonpavde, G, Wright, JL, Yu, EY, Montgomery, RB, Hsieh, AC, Grivas, P & Khaki, AR 2022, 'Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma', Clinical Genitourinary Cancer, vol. 20, no. 6, pp. 558-567. https://doi.org/10.1016/j.clgc.2022.08.006
Warrick, JI, Hu, W, Yamashita, H, Walter, V, Shuman, L, Craig, JM, Gellert, LL, Castro, MAA, Robertson, AG, Kuo, F, Ostrovnaya, I, Sarungbam, J, Chen, YB, Gopalan, A, Sirintrapun, SJ, Fine, SW, Tickoo, SK, Kim, K, Thomas, J, Karan, N, Gao, SP, Clinton, TN, Lenis, AT, Chan, TA, Chen, Z, Rao, M, Hollman, TJ, Li, Y, Socci, ND, Chavan, S, Viale, A, Mohibullah, N, Bochner, BH, Pietzak, EJ, Teo, MY, Iyer, G, Rosenberg, JE, Bajorin, DF, Kaag, M, Merrill, SB, Joshi, M, Adam, R, Taylor, JA, Clark, PE, Raman, JD, Reuter, VE, Chen, Y, Funt, SA, Solit, DB, DeGraff, DJ & Al-Ahmadie, HA 2022, 'Author Correction: FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation (Nature Communications, (2022), 13, 1, (6575), 10.1038/s41467-022-34251-3)', Nature communications, vol. 13, no. 1, 7920. https://doi.org/10.1038/s41467-022-35644-0
Sun, D, Hadjiiski, L, Alva, A, Zakharia, Y, Joshi, M, Chan, HP, Garje, R, Pomerantz, L, Elhag, D, Cohan, RH, Caoili, EM, Kerr, WT, Cha, KH, Kirova-Nedyalkova, G, Davenport, MS, Shankar, PR, Francis, IR, Shampain, K, Meyer, N, Barkmeier, D, Woolen, S, Palmbos, PL, Weizer, AZ, Samala, RK, Zhou, C & Matuszak, M 2022, 'Computerized Decision Support for Bladder Cancer Treatment Response Assessment in CT Urography: Effect on Diagnostic Accuracy in Multi-Institution Multi-Specialty Study', Tomography, vol. 8, no. 2, pp. 644-656. https://doi.org/10.3390/tomography8020054
on behalf of the COVID-19 and Cancer Consortium 2022, 'Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study', Cancers, vol. 14, no. 17, 4334. https://doi.org/10.3390/cancers14174334
on behalf of the Global Society of Rare Genitourinary Tumors (GSRGT) and the International Bladder Cancer Group (IBCG) 2023, 'Disparities in Access to Novel Systemic Therapies in Patients With Urinary Tract Cancer: Propagating Access, Policies and Resources Uniformly', Clinical Genitourinary Cancer, vol. 21, no. 2, pp. 301-308. https://doi.org/10.1016/j.clgc.2022.10.002
Sun, D, Hadjiiski, L, Garje, R, Zakharia, Y, Pomerantz, L, Joshi, M, Alva, A, Chan, HP, Cohan, RH, Caoili, EM, Cha, KH, Kirova-Nedyalkova, G, Davenport, MS, Shankar, PR, Francis, IR, Shampain, K, Meyer, N, Barkmeier, D, Woolen, S, Palmbos, PL, Weizer, AZ, Samala, RK, Zhou, C & Matuszak, M 2022, Effect of computerized decision support on diagnostic accuracy and intra-observer variability in multi-institutional observer performance study for bladder cancer treatment response assessment in CT urography. in K Drukker & KM Iftekharuddin (eds), Medical Imaging 2022: Computer-Aided Diagnosis., 120330G, Progress in Biomedical Optics and Imaging - Proceedings of SPIE, vol. 12033, SPIE, Medical Imaging 2022: Computer-Aided Diagnosis, Virtual, Online, 3/21/22. https://doi.org/10.1117/12.2611179
BLC2001 Study Group 2022, 'Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study', The Lancet Oncology, vol. 23, no. 2, pp. 248-258. https://doi.org/10.1016/S1470-2045(21)00660-4
Weng, X, Shen, C, Van Scoy, LJ, Boltz, M, Joshi, M & Wang, L 2022, 'End-of-Life Costs of Cancer Patients With Alzheimer's Disease and Related Dementias in the U.S.', Journal of Pain and Symptom Management, vol. 64, no. 5, pp. 449-460. https://doi.org/10.1016/j.jpainsymman.2022.07.014
Warrick, JI, Hu, W, Yamashita, H, Walter, V, Shuman, L, Craig, JM, Gellert, LL, Castro, MAA, Robertson, AG, Kuo, F, Ostrovnaya, I, Sarungbam, J, Chen, YB, Gopalan, A, Sirintrapun, SJ, Fine, SW, Tickoo, SK, Kim, K, Thomas, J, Karan, N, Gao, SP, Clinton, TN, Lenis, AT, Chan, TA, Chen, Z, Rao, M, Hollman, TJ, Li, Y, Socci, ND, Chavan, S, Viale, A, Mohibullah, N, Bochner, BH, Pietzak, EJ, Teo, MY, Iyer, G, Rosenberg, JE, Bajorin, DF, Kaag, M, Merrill, SB, Joshi, M, Adam, R, Taylor, JA, Clark, PE, Raman, JD, Reuter, VE, Chen, Y, Funt, SA, Solit, DB, DeGraff, DJ & Al-Ahmadie, HA 2022, 'FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation', Nature communications, vol. 13, no. 1, 6575. https://doi.org/10.1038/s41467-022-34251-3
Talukder, R, Makrakis, D, Diamantopoulos, LN, Carril-Ajuria, L, Castellano, D, De Kouchkovsky, I, Koshkin, VS, Park, JJ, Alva, A, Bilen, MA, Stewart, TF, McKay, RR, Santos, VS, Agarwal, N, Jain, J, Zakharia, Y, Morales-Barrera, R, Devitt, ME, Grant, M, Lythgoe, MP, Pinato, DJ, Nelson, A, Hoimes, CJ, Shreck, E, Gartrell, BA, Sankin, A, Tripathi, A, Zakopoulou, R, Bamias, A, Murgic, J, Fröbe, A, Rodriguez-Vida, A, Drakaki, A, Liu, S, Kumar, V, Lorenzo, GD, Joshi, M, Velho, PI, Buznego, LA, Duran, I, Moses, M, Barata, P, Sonpavde, G, Yu, EY, Wright, JL, Grivas, P & Khaki, AR 2022, 'Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin', Clinical Genitourinary Cancer, vol. 20, no. 2, pp. 165-175. https://doi.org/10.1016/j.clgc.2021.12.012
2021
Khaki, AR, Li, A, Diamantopoulos, LN, Miller, NJ, Carril-Ajuria, L, Castellano, D, De Kouchkovsky, I, Koshkin, V, Park, J, Alva, A, Bilen, MA, Stewart, T, Santos, V, Agarwal, N, Jain, J, Zakharia, Y, Morales-Barrera, R, Devitt, M, Nelson, A, Hoimes, CJ, Shreck, E, Gartrell, BA, Sankin, A, Tripathi, A, Zakopoulou, R, Bamias, A, Rodriguez-Vida, A, Drakaki, A, Liu, S, Kumar, V, Lythgoe, MP, Pinato, DJ, Murgic, J, Fröbe, A, Joshi, M, Isaacsson Velho, P, Hahn, N, Alonso Buznego, L, Duran, I, Moses, M, Barata, P, Galsky, MD, Sonpavde, G, Yu, EY, Shankaran, V, Lyman, GH & Grivas, P 2021, 'A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors', European Urology Oncology, vol. 4, no. 3, pp. 464-472. https://doi.org/10.1016/j.euo.2020.12.006
Schmidt, AL, Tucker, MD, Bakouny, Z, Labaki, C, Hsu, CY, Shyr, Y, Armstrong, AJ, Beer, TM, Bijjula, RR, Bilen, MA, Connell, CF, Dawsey, SJ, Faller, B, Gao, X, Gartrell, BA, Gill, D, Gulati, S, Halabi, S, Hwang, C, Joshi, M, Khaki, AR, Menon, H, Morris, MJ, Puc, M, Russell, KB, Shah, NJ, Sharifi, N, Shaya, J, Schweizer, MT, Steinharter, J, Wulff-Burchfield, EM, Xu, W, Zhu, J, Mishra, S, Grivas, P, Rini, BI, Warner, JL, Zhang, T, Choueiri, TK, Gupta, S & McKay, RR 2021, 'Association between Androgen Deprivation Therapy and Mortality among Patients with Prostate Cancer and COVID-19', JAMA network open, vol. 4, no. 11, e2134330. https://doi.org/10.1001/jamanetworkopen.2021.34330
Makrakis, D, Talukder, R, Diamantopoulos, LN, Carril-Ajuria, L, Castellano, D, De Kouchkovsky, I, Koshkin, VS, Park, JJ, Alva, A, Bilen, MA, Stewart, TF, McKay, RR, Santos, VS, Agarwal, N, Jain, J, Zakharia, Y, Morales-Barrera, R, Devitt, ME, Grant, M, Lythgoe, MP, Pinato, DJ, Nelson, A, Hoimes, CJ, Shreck, E, Gartrell, BA, Sankin, A, Tripathi, A, Zakopoulou, R, Bamias, A, Murgic, J, Fröbe, A, Rodriguez-Vida, A, Drakaki, A, Liu, S, Kumar, V, Di Lorenzo, G, Joshi, M, Isaacsson-Velho, P, Buznego, LA, Duran, I, Moses, M, Barata, P, Sonpavde, G, Yu, EY, Wright, JL, Grivas, P & Khaki, AR 2022, 'Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer', BJU International, vol. 130, no. 5, pp. 592-603. https://doi.org/10.1111/bju.15603
Joshi, M, Holder, SL, Zhu, J, Zheng, H, Komanduri, S, Warrick, J, Yasin, H, Gajre, R, Jia, B, Drabick, JJ, DeGraff, DJ & Zakharia, Y 2022, 'Avelumab in Combination with Eribulin Mesylate in Metastatic Urothelial Carcinoma: BTCRC GU-051, a Phase 1b Study', European Urology Focus, vol. 8, no. 2, pp. 483-490. https://doi.org/10.1016/j.euf.2021.03.005
Nesterova, D, Zhu, J, Kramer, C, Vasekar, M, Truica, C, Joshi, A, Hayes, M, Kessler, J, Saunders, EFH, Drabick, JJ & Joshi, M 2022, 'Group-led creative writing and behavioural health in cancer: A randomised clinical trial', BMJ Supportive and Palliative Care, vol. 12, no. 1, pp. 91-98. https://doi.org/10.1136/bmjspcare-2020-002463
Esagian, SM, Khaki, AR, Diamantopoulos, LN, Carril-Ajuria, L, Castellano, D, De Kouchkovsky, I, Park, JJ, Alva, A, Bilen, MA, Stewart, TF, McKay, RR, Santos, VS, Agarwal, N, Jain, J, Zakharia, Y, Morales-Barrera, R, Devitt, ME, Nelson, A, Hoimes, CJ, Shreck, E, Gartrell, BA, Sankin, A, Tripathi, A, Zakopoulou, R, Bamias, A, Rodriguez-Vida, A, Drakaki, A, Liu, S, Kumar, V, Lythgoe, MP, Pinato, DJ, Murgic, J, Fröbe, A, Joshi, M, Isaacsson Velho, P, Hahn, N, Alonso Buznego, L, Duran, I, Moses, M, Barata, P, Galsky, MD, Sonpavde, G, Yu, EY, Msaouel, P, Koshkin, VS & Grivas, P 2021, 'Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes', BJU International, vol. 128, no. 2, pp. 196-205. https://doi.org/10.1111/bju.15324
Hadjiiski, L, Joshi, M, Alva, A, Chan, HP, Cohan, RH, Caoili, EM, Kirova-Nedyalkova, G, Davenport, MS, Shankar, PR, Francis, IR, Cha, KH, Samala, RK, Palmbos, PL & Weizer, AZ 2021, Multi-institutional observer performance study for bladder cancer treatment response assessment in CT urography with and without computerized decision support. in MA Mazurowski & K Drukker (eds), Medical Imaging 2021: Computer-Aided Diagnosis., 115971K, Progress in Biomedical Optics and Imaging - Proceedings of SPIE, vol. 11597, SPIE, Medical Imaging 2021: Computer-Aided Diagnosis, Virtual, Online, United States, 2/15/21. https://doi.org/10.1117/12.2582331
KEYNOTE-361 Investigators 2021, 'Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial', The Lancet Oncology, vol. 22, no. 7, pp. 931-945. https://doi.org/10.1016/S1470-2045(21)00152-2
2020
The COVID-19 and Cancer Consortium 2020, 'A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance', Cancer Cell, vol. 38, no. 6, pp. 761-766. https://doi.org/10.1016/j.ccell.2020.10.022
Joshi, M, Grivas, P, Mortazavi, A, Monk, P, Clinton, SK, Sue-Ann Woo, M, Holder, SL, Drabick, JJ & Yin, M 2020, 'Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer', Cancer medicine, vol. 9, no. 24, pp. 9365-9372. https://doi.org/10.1002/cam4.3552
COVID-19 and Cancer Consortium 2020, 'Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study', The Lancet, vol. 395, no. 10241, pp. 1907-1918. https://doi.org/10.1016/S0140-6736(20)31187-9
Necchi, A, Madison, R, Pal, SK, Ross, JS, Agarwal, N, Sonpavde, G, Joshi, M, Yin, M, Miller, VA, Grivas, P, Chung, JH & Ali, SM 2021, 'Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma', European Urology Focus, vol. 7, no. 6, pp. 1339-1346. https://doi.org/10.1016/j.euf.2020.08.001
Miller, NJ, Khaki, AR, Diamantopoulos, LN, Bilen, MA, Santos, V, Agarwal, N, Morales-Barrera, R, Devitt, M, Nelson, A, Hoimes, CJ, Shreck, E, Assi, H, Gartrell, BA, Sankin, A, Rodriguez-Vida, A, Lythgoe, M, Pinato, DJ, Drakaki, A, Joshi, M, Isaacsson Velho, P, Hahn, N, Liu, S, Alonso Buznego, L, Duran, I, Moses, M, Jain, J, Murgic, J, Barata, P, Tripathi, A, Zakharia, Y, Galsky, MD, Sonpavde, G, Yu, EY, Lyman, GH & Grivas, P 2020, 'Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study', Journal of Urology, vol. 204, no. 1, pp. 63-69. https://doi.org/10.1097/JU.0000000000000761
Khaki, AR, Li, A, Diamantopoulos, LN, Bilen, MA, Santos, V, Esther, J, Morales-Barrera, R, Devitt, M, Nelson, A, Hoimes, CJ, Shreck, E, Assi, H, Gartrell, BA, Sankin, A, Rodriguez-Vida, A, Lythgoe, M, Pinato, DJ, Drakaki, A, Joshi, M, Isaacsson Velho, P, Hahn, N, Liu, S, Alonso Buznego, L, Duran, I, Moses, M, Jain, J, Murgic, J, Baratam, P, Barata, P, Tripathi, A, Zakharia, Y, Galsky, MD, Sonpavde, G, Yu, EY, Shankaran, V, Lyman, GH & Grivas, P 2020, 'Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors', Cancer, vol. 126, no. 6, pp. 1208-1216. https://doi.org/10.1002/cncr.32645
Dudek, AZ, Liu, LC, Gupta, S, Logan, TF, Singer, EA, Joshi, M, Zakharia, YN, Lang, JM, Schwarz, JK, Al-Janadi, A & Alva, AS 2020, 'Phase Ib/II clinical trial of pembrolizumab with bevacizumab for metastatic renal cell carcinoma: BTCRC-GU14-003', Journal of Clinical Oncology, vol. 38, no. 11, pp. 1138-1145. https://doi.org/10.1200/JCO.19.02394
Yin, M, Grivas, P, Wang, QE, Mortazavi, A, Emamekhoo, H, Holder, SL, Drabick, JJ, Woo, MSA, Pal, S, Vasekar, M, Folefac, E, Clinton, SK, Monk, P & Joshi, M 2020, 'Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer', Oncologist, vol. 25, no. 8, pp. 680-688. https://doi.org/10.1634/theoncologist.2019-0851
2019
Voss, MH, Bhatt, RS, Vogelzang, NJ, Fishman, M, Alter, RS, Rini, BI, Beck, JT, Joshi, M, Hauke, R, Atkins, MB, Burgess, E, Logan, TF, Shaffer, D, Parikh, R, Moazzam, N, Zhang, X, Glasser, C, Sherman, ML & Plimack, ER 2019, 'A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma', Cancer, vol. 125, no. 14, pp. 2400-2408. https://doi.org/10.1002/cncr.32061
Joshi, A, Hillwig-Garcia, J, Joshi, M, Lehman, E, Khan, A, Llorente, A & Haidet, P 2019, 'Comics as an Educational Tool on a Clinical Clerkship', Academic Psychiatry, vol. 43, no. 3, pp. 290-293. https://doi.org/10.1007/s40596-018-1016-1
Yin, M, Zhao, J, Monk, P, Martin, D, Folefac, E, Joshi, M, Jin, N, Mortazavi, A, Verschraegen, C & Clinton, S 2020, 'Comparative effectiveness of surgery versus external beam radiation with/without brachytherapy in high-risk localized prostate cancer', Cancer medicine, vol. 9, no. 1, pp. 27-34. https://doi.org/10.1002/cam4.2605
Zhu, J, Hussain, M, Joshi, A, Truica, CI, Nesterova, D, Collins, J, Saunders, EFH, Hayes, M, Drabick, JJ & Joshi, M 2020, 'Effect of creative writing on mood in patients with cancer', BMJ Supportive and Palliative Care, vol. 10, no. 1, pp. 64-67. https://doi.org/10.1136/bmjspcare-2018-001710
Loriot, Y, Necchi, A, Park, SH, Garcia-Donas, J, Huddart, R, Burgess, E, Fleming, M, Rezazadeh, A, Mellado, B, Varlamov, S, Joshi, M, Duran, I, Tagawa, ST, Zakharia, Y, Zhong, B, Stuyckens, K, Santiago-Walker, A, De Porre, P, O'Hagan, A, Avadhani, A & Siefker-Radtke, AO 2019, 'Erdafitinib in locally advanced or metastatic urothelial carcinoma', New England Journal of Medicine, vol. 381, no. 4, pp. 338-348. https://doi.org/10.1056/NEJMoa1817323
Zaleski, M, Gogoj, A, Walter, V, Raman, JD, Kaag, M, Merrill, SB, Drabick, J, Joshi, M, Holder, S, DeGraff, DJ & Warrick, JI 2019, 'Mitotic activity in noninvasive papillary urothelial carcinoma: its value in predicting tumor recurrence and comparison with the contemporary 2-tier grading system', Human Pathology, vol. 84, pp. 275-282. https://doi.org/10.1016/j.humpath.2018.10.008
Joshi, M, Warrick, JI, Yin, M, Holder, SL & Drabick, JJ 2019, 'Need for a personalized approach for muscle invasive bladder cancer: Role of tumor biology in response to neoadjuvant chemotherapy', Translational Andrology and Urology, vol. 8, pp. S99-S103. https://doi.org/10.21037/tau.2018.12.04
Semrad, TJ, Groshen, S, Luo, C, Pal, S, Vaishampayan, U, Joshi, M, Quinn, DI, MacK, PC, Gandara, DR & Lara, PN 2019, 'Randomized phase 2 study of trebananib (AMG 386) with or without continued anti-vascular endothelial growth factor therapy in patients with renal cell carcinoma who have progressed on bevacizumab, pazopanib, sorafenib, or sunitinib-Results of NCI/CTEP protocol 9048', Kidney Cancer, vol. 3, no. 1, pp. 51-61. https://doi.org/10.3233/KCA-180041